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1. Introduction 
Ameloblastoma, a benign odontogenic tumor, has locally invasive 
behavior with high recurrence rate. The etiological factors of ameloblastoma 
remain unknown, although it has been known for about two hundred years. 
Ameloblastoma was first reported by Cusack et al.(1) in 1827 and then Broca et 
al.(2) in 1868. Until 1885, Malassez(3) proposed the name “epithelioma 
adamentin” for solid/multicystic ameloblastoma and the term ameloblastoma 
which is currently used was re-named by Ivey and Churchill(4) in 1930. The 
several etiological factors such as caries, trauma, infection, inflammation, or 
extraction, tooth eruption, nutritional deficit disorders, and Human papilloma 
virus (HPV)(5,6,7) as well as ameloblastin deficiency(8) have been considered in 
recent articles but these factors have been controversial and not 
conclusive(9,10,11,12,13). According to World Health Organization (WHO) 
classification(14,15), ameloblastomas are divided into 4 subtypes: 
solid/multicystic ameloblastoma (SMA), unicystic ameloblastoma (UA), 
desmoplastic ameloblastoma (DA) and extraosseous (peripheral) 
ameloblastoma (EA). Two growth patterns including follicular pattern and 
plexiform pattern were recognized in ameloblastomas. 
Patients with ameloblastomas occurred in 4 to 92 year-old with no 
significant difference in gender(16). Ameloblastoma grows slowly and often 
results in swelling on face. The tumors enlarge their size with destraction of the 
cortical bone and the roots of teeth as well as with infiltration into the soft 
tissue. Delayed tooth eruption, tooth displacement, ulceration, pain and 
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1. Introduction 
paresthesia of lower lip were occasionally found in clinical findings from the 
patients with ameloblastomas(16). The ratio between maxillary and mandibular 
ameloblastomas were reported as 1:5.8(16). Unicystic ameloblastoma was often 
seen in young patients (the mean of age was 26.3 years) whereas 
solid/multicystic one in patients with higher age (the mean of age was 41.4 
years)(16).  
Nakamura et al.(17) advocated for conservative treatment but conservative 
treatment leads high recurrence rate. Chapelle et al.(18) recommended radical 
treatment for solid/multicystic ameloblastoma and unicystic ameloblastoma 
with aggressively histopathological features such as mural/intra mural 
ameloblastomas. The patients, then, should be followed up for at least 10 
years. 
The p53 protein, tumor suppressor protein, is the cellular gatekeeper 
against the formation of tumors. In normal cells, wild-type p53 protein is 
maintained at a low concentration due to its short half-life (about 20 minutes) 
and can inhibit cell proliferation. The loss of its function due to the mutation or 
alteration of the structure of p53 gene is also associated with increase its 
concentration as its extended half-life(19,20). In addition, the expression of p53 in 
benign ameloblastoma was significantly higher than that in normal tissue(21). On 
the other hand, pRB, the product of the retinoblastoma tumor suppressor 
gene, plays an important role in regulation of not only cell proliferation but also 
apotosis(22). As we have known that Ki67 protein is well known as a marker of 
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1. Introduction 
cell proliferation expressed during all active phases of cell cycle except G0. The 
immuno-reactivity of Ki67 in previous study has showed similar distribution to 
that for Retinoblastoma protein (pRB) in ameloblastomas(23). Moreover, 
fibroblast growth factor (FGF) signaling pathway was implicated as a key driver 
of tumor progression and growth including angiogenesis, proliferation, 
migration and differentiation, and cell survival as well as 
angiogenesis(24,25,26,27,28). In particular, FGF-1 and FGF-2 have been shown as 
angiogenesis(25,26,27,28) and can directly affect tumor angiogenesis by promoting 
the cellular proliferation of endothelial cells(26,29). FGF-1 and FGF-2 has been 
shown to contribute to the growth and development of ameloblastomas(30). 
Furthermore, heparin-binding protein 17/fibroblast growth factor-binding 
protein-1 (HBp17/FGFBP-1) is secreted protein which was first purified from 
culture medium conditioned by human epidermoid carcinoma cell line A431-
AJC(31). HBp17/FGFBP-1 can bind FGF-1 and FGF-2 in a reversible, noncovalent 
manner and release them from the extracellular matrix(31,32). Several studies 
showed that HBp17/FGFBP-1 might enhance FGF effect leading angiogenesis, 
tumor proliferation, migration and differentiation(24,25,26,27,33,34). 
There have been several  studies which evaluate the expression of Ki67, 
p53, pRB, FGF-1, FGF-2 as well as microvessel density (MVD) in ameloblastoma 
since then, but little is known about the correlation of pRB with Ki67, p53 as 
well as the expression and the correlations of HBp17/FGFBP-1 and FGF-1, FGF-
2, MVD in ameloblastomas and the etiological features as well.  
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1. Introduction 
Aim of study 
To elucidate the molecular etiological roles and the correlations of pRB, 
p53, Ki67, HBp17/FGFBP-1, FGF-1, FGF-2, and CD34 in ameloblastomas, the 
expression of these factors was studied immunohistochemically and examined 
the correlation between the each protein expression statistically. 
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2. Materials and Methods 
Tissue samples of ameloblastomas from both of National Hospital of 
Odonto-Stomatology at Ho Chi Minh city, Viet Nam and Hiroshima University 
Hospital, Hiroshima, Japan were collected and studied reactivity for 
HBp17/FGFBp-1, FGF-1, FGF-2, CD34, p53, pRB and Ki67 markers 
immunohistochemically. All tissue samples were fixed in 10% neutral buffered 
formalin (Wako Pure Chemical Industries, Ltd. Osaka; Vinachem, Viet Nam) and 
embedded in paraffin (Histprep 580, Wako).The sections were prepared at 4 
µm thickness for immunohistochemical procedures by using antibodies of 
HBp17/FGFBP-1, FGF1, FGF2, CD34, p53, pRB and Ki67 as shown in Table 1. This 
study has been approved by the Ethics Committee in Hiroshima University. 
Heat-induced epitope retrieval method 
For antigen retrieval, deparaffinized sections were pre-treated using heat-
induced epitope retrieval method before blocking endogenous peroxidase 
activity. 
For Ki67, pRB and CD34 antigen retrieval, Dako Target retrieval solution 
(pH 6.0, Dako, Glostrup, Denmark) was used. For p53 antigen retrieval, Tris-
EDTA retrieval buffer (10mM Tris Base, 1mM EDTA solution, pH 9.0) was used.  
Deparaffinized sections in the retrieval solution were pre-treated in 
microwave until the retrieval solution comes to boil (about 6 minutes), then 
further incubate them in the boiling water for 30-60 minutes. 
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2. Materials and Methods 
Immunohistochemistry 
After blocking endogenous peroxidase activity using 3% hydrogen 
peroxide (H2O2) (Wako) diluted in methanol (Nacalai tesque, Kyoto) for 30 
minutes at room temperature, the sections were incubated with 10% normal 
goat serum (Histofine, Nichirei Bioscience Inc., Tokyo) at room temperature for 
10 minutes to prevent non-specific binding and then incubated overnight with 
primary antibodies as shown in Table 1, at 40C. 
For double antigens (CD34 and Ki67 (or p53)) staining, the sections were 
incubated with first primary antibody of CD34 for 30 minutes at room 
temperature, then further incubated overnight with second primary antibody 
of Ki67 or p53 followed by incubation with the corresponding secondary 
antibodies as shown in Table 1 for 30 minutes at room temperature. 
As negative controls, sections were probed with diluted antibody solution 
except for primary antibody, or negative control mouse IgG1 (code X0931, 
Dako). As positive controls, sections from squamous cell carcinoma tissues and 
normal oral tissues were used. 
The immuno-reactivities were visualized by using Dako Envision+System-
HRP kits (Dako). The sections were then counterstained with Mayer’s Hemalum 
solution (Merck, Germany) and permanently mounted. 
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2. Materials and Methods 
Evaluations 
For evaluating the expression of these factors, the sections were scanned 
at low magnification for localization of positive cells areas and microvessels’ 
hot spots. Several fields, randomly selected were transferred to digital 
photomicrographs using Leica system (Leica DFC camera, type Leica DC500, 
Leica microsystems Imaging solution Ltd.,Tokyo). An ImageJ software (ImageJ 
1.42q, public domain software, available at http://rsb.info.nih.gov/ij/index.html 
developed by Wayne Rasband) was used to count the number of positive 
tumor cells, number of negative tumor cells, tumor optical density (TOD), 
stroma optical density (SOD), optical density of the absolute white color, 
number of microvessels, the area of microvessels as well as the area of stroma.  
Evaluation of HBp17/FGFBP-1, FGF1, FGF2, p53, pRB and Ki67 expression 
Several randomized fields (x400) were selected and transfered to digital 
photomicrographs of 1300x1034 pixels using Leica system. By using the criteria 
and the results of previous studies(30,35,36,37), only cytoplasmic immuno-
reactivity for HBp17/FGFBP-1, FGF1, FGF2 and only nuclear reactivity of pRB 
above any cytoplasmic background as well as nulcear immunoreactivity for 
p53, Ki67 were considered and evaluated as positive staining. At least 1000 
tumor cells were counted. For evaluation of HBp17/FGFBP-1, FGF1, FGF2, p53, 
pRB and Ki67 expression, the labeling index (LI) and the digital expression index 
(dEI) were used according to the following formulas:  
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2. Materials and Methods 
Labeling index (LI): 
 
                                     LI =                                     100(%) 
 
Digital immunostaining intensity (dISI): to count the digital 
immunostaining intensity (dISI), the same photomicrographs used for the 
counting LI were studied. 10 randomly selected regions from different positive 
tumor cells’ areas and stroma’s areas were indicated by using a “10-pixel-brush 
selections”- a tool of ImageJ software. The tumor optical density (TOD) and the 
stroma optical density (SOD) were then calculated. Optical density is the 
average of red, green and blue color component (RGB), expressed in optical 
units per pixel (ou/pixel). The absolute white color composed by the totality of 
red, green, and blue that corresponds to the maximum optical density (255 
ou/pixel); and the absolute black color is the absence of these colors (0 
ou/pixel). The formula below was used to calculate the digital immunostaining 
intensity (dISI). The value of each case was made up an increasing scale by 
equalizing with the stroma optical density and proportional to the optical 
density of the absolute white color(38). 
Digital immunostaining intensity (dISI): 
 
                                 dISI =                             (ou/pixel) 
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2. Materials and Methods 
The digital expression index (dEI) is obtained by multiplying the LI and the 
digital immunostaining intensity (dISI). 
Digital expression index (dEI): 
 
                                     dEI =                    (ou/pixel) 
 
Evaluation of CD34 expression for tumor microvessels analysis:  
The endothelial cells in microvessels were stained strongly and exclusively 
with CD34 marker. After scanning several areas within 500 µm around the 
tumor islands or in the center of tumor islands or within 500 µm under 
basement membrane at 200-fold magnification(39), 5 highest microvessels areas 
(hot spots) were selected. These selected areas (440x350µm) were transfered 
to digital photomicrographs of 1300x1034 pixels with Leica system. Based on 
the criteria of Weidner et al.(40), any positive endothelial cell or endothelial-cell 
cluster that was clearly separate from adjacent microvessels, tumor cells, and 
other connective-tissue elements was regarded as a distinct microvessel. Red 
cells were not required, nor were the presence of vessel lumens. By using 
ImageJ software, the area of CD34-positive microvessels and the area of stroma 
in each selected field as well as the number of microvessels were counted. 
Microvessel density (MVD), which defined as number of microvessels per mm2 
stroma and the percentage of total microvessel area size in stroma (pTS) (%) 
were assessed according to the following formulas: 
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2. Materials and Methods 
Microvessel density (MVD): 
                                  
 MVD =  
 
Percentage of total microvessel area size in stroma (pTS): 
 
                                    pTS=                                          100 (%) 
 
Evaluation of tumor size: 
The estimated tumor volume (eV) has been calculated based on 
orthopanthomogram. By using a millimeter (mm) ruler, the height (H, mm) and 
the length (L, mm) of ameloblastoma were measured on orthopanthomogram. 
The eV was calculated according to the following formula: 
 Estimated tumor volume (eV): 
 
          eV=            (mm3) 
 
Statistical analysis 
The Spearman’s rank correlation test was used to examine statistical 
correlations of each protein expression of HBp17/FGFBP-1, FGF-1, FGF-2, p53, 
pRB, Ki67 and MVD, pTS as well as the estimated tumor volume. Scatter plots 
with the correlation lines were used to show the significant correlations 
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2. Materials and Methods 
between them. The significance is indicated by the p value. Asterisk * indicates 
significant correlation (p<0.05). Wilcoxon signed-rank test (Mann-Whitney U 
test) was also used to examine the differences of HBp17/FGFBP-1 dEI, FGF1 dEI, 
FGF2 dEI, p53 dEI, pRB dEI, Ki67 dEI, MVD and pTS between the 
solid/multicystic ameloblastomas (SMA) and unicystic ameloblastomas (UA). 
Kruskal-Wallis test was used to examine the significant difference in the 
expression of these factors among groups of age. 
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3. Results 
Clinical and histological characteristics of ameloblastomas 
Twenty nine cases of benign ameloblastoma from 15 women and 14 men 
were studied (Table 2). The follicular patterns and the plexiform patterns 
(Figure 1A, 1B) in solid/multicystic ameloblastomas were occasionally seen in 
the same sections of the samples (data not shown). Twenty four 
ameloblastomas were found in the posterior mandible and 5 cases in the 
anterior mandible. Radical treatment such as mandibular resection was 
performed for 16 cases of benign ameloblastomas, all from National Hospital of 
Odonto-Stomatology at Ho Chi Minh city and conservative treatment such as 
marsupialization or enucleation was performed for 13 cases from Hiroshima 
University Hospital. Eight cases were recured after conservative treatment. 
No case of ameloblastoma in maxillary was collected. Two cases of 
ameloblastic carcinoma also collected and the malignant cases were also 
included in this study (Table 2). 
Expression of HBp17/FGFBP-1, FGF-1, FGF-2, CD34, p53, pRB and Ki67 in 
ameloblastomas 
Immunohistochemical reactivity for HBp17/FGFBP-1 in ameloblastomas 
was mainly observed in the membrane and cytoplasm of the peripheral/basal 
cells, in the squamous cells as well as in the stellate reticulum-like cells (Figure 
2A, 2B, 2C, 2D). The strongest staining intensity was seen in the squamous cells 
and in the peripheral/basal cells. 
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3. Results 
FGF1-positive staining was mainly observed in the squamous cells and in 
the cytoplasm of the peripheral/basal cells with the expansion into the stellate 
reticulum-like cell areas (Figure 3A, 3B, 3C, 3D). Squamous cells and 
peripheral/basal cells exhibited strong staining intensity.  
The expression of FGF-2 was mainly detected in the membrane and in the 
cytoplasm of the peripheral/basal cells as well as in the squamous cells with 
spreading to the stellate reticulum-like cells (Figure 4A, 4B, 4C, 4D). The stellate 
reticulum-like cells areas showed weaker staining intensity compare to that in 
the squamous cells and in the peripheral/basal cells areas. 
HBp17/FGFBP-1, FGF-1, and FGF-2- positive staining was occasionally seen 
in the nuclei of tumor cells. 
Tumor microvessels with endothelial cells expressing strong staining 
intensity of CD34 showed slightly irregular shaped, tortuous and dilated form in 
the stroma (Figure 5A, 5B, 5C, 5D). Follicular patterns (Figure 5A, 5C) showed 
many small microvessels with slightly irregular shape, whereas microvessels in 
plexiform patterns were scattered with dilated shape (Figure 5B, 5D). 
The immunohistochemical reactivity for p53 was detected in the nuclei of 
peripheral/basal cells with spreading to the stellate reticulum-like cells (Figure 
6A, 6B, 6C, 6D). The p53-positive cells in the reticulum-like cell area showed 
lower intensity than that in the peripheral/basal cell area. 
Immunohistochemical reactivity for pRB in ameloblastomas was mainly 
recognized in the nuclei of the tumor cells (Figure 7A, 7B, 7C, 7D). The pRB-
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3. Results 
positive cells in the peripheral/basal areas exhibited stronger staining intensity 
than those in the stellate reticulum-like areas. 
The expression of Ki67 protein in ameloblastomas was observed in nuclei 
of tumor cells with strong immunostaining intensity (Figure 8A, 8B, 8C, 8D). A 
few scattered Ki67-positive cells were observed in the peripheral/basal cells 
and occasionally seen in the stellate reticulum-like cells. There is no significant 
difference in an intensity of Ki67-positive cells between the stellate reticulum-
like cell area and the peripheral/basal cell area. 
Double Ki67-CD34 antigens staining 
The higher expression of Ki67 in tumor cells was associated with an 
increase in microvessels around tumors islands (Figure 9A, 9B, 9C, 9D). Tumor 
islands with high expression of Ki67 accompanied  with many small 
microvessels with irregular shape in tumor of follicular patterns (Figure 9A, 9B) 
whereas  tumor islands with high expression of Ki67 have very few microvessels 
with dilated shape in plexiform patterns (Figure 9C, 9D). 
Correlation between p53, pRB and Ki67  
It has been found that p53 dEI positively correlated with Ki67 dEI (p=0.02) 
(Figure 10B, Table 3B) whereas no correlation between p53 LI and Ki67 LI 
(p=0.094) has been observed (Figure 10A, Table 3A). 
The positive correlations between pRB and p53, Ki67 were revealed in the 
scatter plots (Figure 11). By using the Spearman rank correlation’s test, the LI of 
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3. Results 
pRB showed significantly positive correlation with that of p53 (p<0.001) and 
that of Ki67 (p=0.003) (Figure 11A, Table 3A). In addition, the dEI of pRB 
showed significantly positive correlation with that of p53 (p<0.001) and that of 
Ki67 (p=0.009) (Figure 11B, Table 3B). 
Correlation between Ki67 and MVD and pTS 
 It has been found that pTS correlated well with Ki67 LI (p=0.001) and 
Ki67 dEI (p=0.002) (Figure 12B) but MVD did not correlated with Ki67 LI 
(p=0.157) and Ki67 dEI (p=0.221) (Figure 12A). 
Correlation between tumor angiogenesis, tumor microvessels and tumor 
proliferation 
The dEI of HBp17/FGFBP-1 has significantly positive correlation with FGF-1 
dEI (p<0.001), FGF-2 dEI (p<0.001), MVD (p<0.001), and pTS (p<0.001) (Figure 
13A, 13B; Table 5). The significantly positive correlation between pTS with FGF-
1 dEI (p<0.001), and FGF-2 dEI (p<0.001) as well as MVD with FGF-1 dEI 
(p<0.001), and FGF-2 dEI (p<0.001) are also found in this study (Table 5). 
The dEI of Ki67 also correlated with HBp17/FGFBP-1 dEI (0.002), FGF-1 dEI 
(p=0.004), and FGF-2 dEI (p=0.038) (Figure 14, Table 5). 
The role of p53 in tumor angiogenesis in ameloblastomas 
The positive correlation of p53 and HBp17/FGFBP-1, FGF-1, FGF-2, MVD 
and pTS was obtained (p<0.001) on the scatter plots analysis (Figure 15A, 15B). 
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3. Results 
Correlation of the expression of several factors with tumor size 
(estimated tumor volume) 
An eV calculated from orthopanthomogram significantly correlated with 
HBp17/FGFBP-1 dEI (p=0.024) and pRB dEI (p=0.008) (Figure 16). There is no 
significant correlation between eV and the expression of other factors (p>0.05). 
Correlation of the expression of several factors with age 
The age of patients with ameloblastmas were divided into 3 groups, group 
1 with patients younger than 20 years, group 2: patients from 20-40 years and 
groups 3 with patients older than 40 years. It has been found that pRB dEI, and 
pRB LI showed significant difference amongst three groups of age (Table 6). 
Relationship between the expression of several factors and the gender 
and location of tumors 
There was no significant gender and location difference in the expression 
of these factors. 
Difference in the expression of the various factors between SMA and UA 
The p53 LI in SMA was significantly higher than that in UA (p=0.046) 
whereas the dISI of p53 in UA was significantly higher than that in SMA 
(p=0.036). There is no difference in dEI of p53 between SMA and UA (p=0.178) 
(Table 7). 
Moreover, there is no difference in the expression of HBp17/FGFBP-1, 
FGF-1, FGF-2, CD34, pRB and Ki67 between SMA and UA (Table 7). 
   
 
 
Page 
17 
 
3. Results 
Other results 
The expression of the  factors in ameloblastic carcinoma was higher than 
that in benign ameloblastomas, but due to small sample size, the statistical 
comparison of the expression of these factors between malignant and benign 
ameloblastomas could not be performed (Table 8). 
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4. Discussion 
The p53 protein, tumor suppressor protein, is the cellular gatekeeper 
against the formation of tumors due to its ability to protect the genome by 
responding to genotoxic stress, such as DNA damage and other stress signals. 
In normal cells, wild-type p53 is maintained at a low concentration due to its 
short half-life (about 20 minutes). The loss of its function either due to 
mutation or alteration of the structure of p53 gene is also associated with 
increased its concentration as its extended half-life(19,20). Kumamoto et al.(21) 
showed that the expression of p53 in ameloblastomas was significantly higher 
than that in normal tissues suggesting the abnormal p53 in ameloblastomas 
might be the results of the loss of its function leading to the formation and the 
development of ameloblastomas. Although several studies demonstrated 
existence of mutation of p53 in ameloblastomas, there has been speculated 
that the mutation might play a minor role in neoplastic changes of 
ameloblastomas(21,41,42,43). In this study, an immunohistochemical reactivity for 
p53 was seen in the nuclei of peripheral/basal cells with spreading of p53-
positive cells to the stellate reticulum-like cells. The p53-positive staining 
intensity in the peripheral areas exhibited stronger than that in the stellate 
reticulum-like cells areas. 
It has been reported that the expression of Ki67 protein reflecting to 
cellular proliferation ability expressed maximally during S-phase and rapidly 
degraded after mitosis. Thus it has been known that Ki67 is an useful marker to 
predict for tumor development(44,45). In ameloblastomas, a few scattered Ki67-
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4. Discussion 
positive cells were observed only limited area in the peripheral/basal areas, at 
where the proliferating tumor cells exist in ameloblastoma(46,47,48) although 
some positive cells were detected in the stellate reticulum-like cells areas.  The 
staining intensity of Ki67-positive cells in  the stellate reticulum-like cell areas is 
similar to  that of the peripheral/basal cell areas. 
Normally, p53 can inhibit cell proliferation but loss of its function results in 
increased proliferation. Several studies demonstrated the correlation between 
p53 and Ki67 in tumors(39,49,50). Slootweg(51) demonstrated that increased p53 
staining intensity rather than increased the number of p53-positive cells was 
well related to proliferation in odontogenic epithelium. In my study, the 
significantly positive correlation between p53 dEI and Ki67 dEI was found 
whereas the correlation between p53 LI and Ki67 LI was not observed, 
suggesting dEI is more useful indicator compare to LI in evaluating the 
immunohistochemical expression.  
Besides, tumor growth is the result of the interaction between cell 
proliferation and cell death in which the balance between proliferation and 
apoptosis plays an important role in tumor growth(22,33,45,52,53,54,55).  In normal 
tissue, the balance between proliferation and apoptosis is maintained(54,56) 
whereas in ameloblastomas, the positive correlation between p53 and Ki67 
showed the loss of this balance. In addition, pRB, the product of the 
retinoblastoma tumor suppressor gene, plays an important role in regulation of 
not only cell proliferation but also apotosis(54,57,58). The pRB can repress 
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transcription by at least two different mechanisms: bind E2Fs and block their 
ability to activate transcription; pRB-E2F repressor complex that forms at 
promoters can actively repress transcription(22). Thus, pRB can inhibit cell 
proliferation. Although several studies showed the role of HPV in inhibition of 
pRB(59), there is no evidence whether HPV works as the etiologically important  
role in ameloblastomas(10,13). Recent study suggested that the presence of HPV-
DNA in ameloblastomas could be explained by secondary surgically acquired 
contamination from the surface mucosal epithelium than a true integration of 
HPV-DNA in human genome(9). On the other hand, pRB can regulate the 
apoptotic function as an upstream regulator of p53(60) through binding to 
MDM2, thus it might protect p53 from MDM2-targeted degradation by 
occupying a site on MDM2(61). However, pRB can regulate the cell proliferation 
and apoptosis through the phosphorylation cycle, in which 
hyperphosphorylated pRB repeals the interaction with E2F allowing free E2Fs 
to control the expression of several genes that are involved in the cell 
proliferation and apoptosis(22). Thus, pRB plays an important role in the 
regulation of the balance between proliferation and apoptosis.  
In this study, the immunohistochemical reactivity for pRB is mainly 
observed in the nuclei and occasionally seen in the cytoplasm. The pRB-positive 
cells in the peripheral/basal areas exhibited stronger staining intensities than 
those in the stellate reticulum-like areas. In this study, the positive correlation 
between the expression of pRB and the expression Ki67 has been found. This 
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result is in good agreement with the previous reports that the expression of 
pRB correlated with cell proliferation of neoplastic odontgenic epithelial cells 
(22,23,54,62,63,64,65). The positive correlation between pRB and Ki67 in 
ameloblastoma suggested the loss of precise function of pRB in inhibition of 
the growth leading proliferation. While pRB can regulate the apoptotic function 
as an upstream regulator of p53(60), p53 also has ability to induce expression of 
p21, which in turn can shut down the cyclin-CDK complexes leading G1/S arrest 
and therefore maintains pRB in the growth suppression state(66). The positive 
correlation between the expression of pRB and p53 obtained in this study 
strongly suggests the close relationship between pRB and p53 in 
ameloblastomas. As pRB plays an important role in the balance between the 
proliferation and apoptosis, the loss of this balance due to the loss of precise 
function of either pRB or p53 might be involved in the etiology of 
ameloblastomas. 
Angiogenesis has been well known to play an important role in 
development, and progression of tumors(67.68). It has been well known that 
tumors are not able to enlarge their size bigger than 2.5 mm in diameter 
without recruiting new microvessels(28,68,69). A CD34 is a monomeric 
glycoprotein that shows strong and exclusive expression in the endothelial 
cells. Its expression is often used to evaluate microvessel density (MVD) in 
tumors(70,71,72). According to Weidner et al.(40), any positive endothelial cell or 
endothelial-cell cluster that was clearly separate from adjacent microvessels, 
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tumor cells, and other connective-tissue elements was regarded as a distinct 
microvessel. Red cells were not required, nor were the presence of microvessel 
lumens. Single cell sprouts as well as large size of microvessels were included in 
the counts. A cross-sectional area size of microvessel is not mentioned whether 
its size is small or large. Even more than once of distinct clusters given by one 
large size of microvessel by the transected plane, these distinct clusters should 
be regarded as separate microvessels and they were included in the counts 
leading high MVD. Tumor with high MVD means tumor has a lot of 
microvessels in a field but the amount of blood supply could depend not only 
on the number of microvessels but also on the volume of microvessels. The 
amount of blood supply of a small number of large volumes of microvessels 
could be similar to that of a higher number of small volumes of microvessels 
around tumor islands. This suggests that the larger the dilatation of tumor 
microvessels, the more increased the surface area of microvessels and the 
higher the blood supply(73). High MVD and pTS have been considered as the 
result of increased angiogenesis(74). In this study, pTS but not MVD correlated 
well with Ki67 suggesting increase in the percentage of microvessels area size 
in stroma rather than increase in the number of microvessels correlated with 
tumor proliferation. The percentage of microvessels area size in stroma might 
play an important indicator in the growth of ameloblastomas.  
A secreted protein, Heparin-binding protein 17/fibroblast growth factor-
binding protein-1 (HBp17/FGFBP-1), was first purified from culture medium 
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conditioned by human epidermoid carcinoma cell line A431-AJC(31). It has been 
well known that HBp17/FGFBP-1 plays an important role in tumor angiogenesis 
as well as in tumor growth and progression(75,76). HBp17/FGFBP-1 can bind FGF-
1 and FGF-2 in a reversible, noncovalent manner and release them from the 
extracellular matrix(31,32). In addition, several studies showed HBp17/FGFBP-1 
enhanced the effects of FGFs leading angiogenesis, tumor proliferation, 
migration and differentiation(24,25,26,27,33,34). The expression of HBp17/FGFBP-1 
was overexpressed in tumor cells compare to normal epithelial cells(29,35). In 
ameloblastomas, expression of HBp17/FGFBP-1 was found in the membrane 
and cytoplasm of peripheral/basal cells, in the cytoplasm of the stellate 
reticulum-like cells, as well as in the squamous cells although the strongest 
staining intensities were seen in the squamous cells and the peripheral/basal 
cells. The nuclei of tumor cells were occasionally detected positive reactivity for 
HBp17/FGFBP-1. These suggest that HBp17/FGFBP-1 might be produced and 
secreted by ameloblastoma cells and play roles in regulation of tumor 
angiogenesis and stimulation of tumor progression. 
Fibroblast growth factor (FGF) signaling pathway is well known as a key 
driver of tumor progression and growth including wound repair, cell 
proliferation, migration, differentiation, and cell survival as well as 
angiogenesis(24,25,26,27). Aberrations in this signaling pathway may drive 
tumorigenesis(25). FGFs such as FGF-1 and FGF-2 have been shown as 
angiogenic factors(25,26,27,70) and can directly affect tumor angiogenesis by 
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promoting the cellular proliferation of endothelial cells(26,29). Besides, several 
studies showed FGF-1 and FGF-2 had an important role for new blood vessel 
growth(67,77) and FGF-2 was a powerful inducer of angiogenesis which was twice 
as poweful as VEGF(33). In previous study, it has been shown that both FGF-1 
and FGF-2 contribute to the growth and the development of ameloblastomas 
by culturing ameloblastoma-derived tumor cells(30). In this study, important role 
of FGF-1 and FGF-2 in tumor angiogenesis has been revealed by the 
significantly positive correlation of FGF-1 dEI and FGF-2 dEI with MVD and pTS. 
Moreover, HBp17/FGFBP-1 dEI has had significant correlation with FGF-1, 
FGF-2 and MVD, pTS in this study. The results were in agreement with previous 
studies by Aigner A. et al.(78). They showed that HBp17/FGFBP-1 can serve as an 
angiogenic switch molecule of which down-regulation showed inhibition of 
angiogenesis. Moreover, Ray R. et al.(79) reported that up-regulation of 
HBp17/FGFBP-1 was significantly correlated with increased MVD. These results 
strongly suggest the important role of HBp17/FGFBp-1 in the growth and 
progression of amleoblastomas. Taken together, HBp17/FGFBP-1 together with 
FGF-1, FGF-2 might play important roles in the progression of tumor growth 
through stimulating tumor angiogenesis and growth in ameloblastomas. 
It has been demonstrated that p53 protein has roles in tumor growth 
suppressor and in apoptosis including cell cycle arrest, DNA repair, 
programmed cell death as well as the role in inhibition of tumor 
angiogenesis(19,20,39,80,81). In normal cells, p53 protein can inhibit angiogenesis by 
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at least three mechanisms: 1) interfering with central regulators of hypoxia that 
mediate angiogenesis; 2) inhibiting production of proangiogeneic factors; 3) 
directly increasing the production of endogenous angiogenesis inhibitors(20). 
The combinatory effects allow p53 to inhibit angiogenesis. Loss of its function 
can reverse these effects, as consequence, p53 can induce angiogenesis. 
Bergers et al.(80) demonstrated that wild-type p53 inhibits vascular endothelial 
growth factor (VEGF) transcription and prevent progression of tumors and their 
metastases whereas cells with p53 defects have up-regulated the expression of 
VEGF leading tumor angiogenesis. In this study, p53 expression is significantly 
correlated with that of HBp17/FGFBP-1, FGF-1, FGF-2, MVD, pTS, suggesting 
the function of p53 in tumor angiogensis in ameloblastomas.The expression of 
pRB might be influenced by tumor size and age of the patients in 
ameloblastomas. Moreover, tumor size might also influence the expression of 
HBp17/FGFBP-1. The process of tumor growth and invasion in SMA might be 
same as that in UA.  
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1. The dEI is more useful indicator than LI in evaluating the 
immunohistochemical expression. 
2. The increase in percentage of microvessel area size in stroma rather 
than increase in number of microvessels correlated with tumor growth 
and progression in ameloblastomas. 
3. The HBp17/FGFBP-1 together with FGF-1, FGF-2 play an important role 
in the progression of the tumor growth through stimulating tumor 
growth and angiogenesis in ameloblastomas. 
4. The p53 plays an important role in inducing tumor angiogenesis in 
ameloblastomas. 
5. The loss of the balance between proliferation and apoptosis due to the 
loss of precise function of either p53 or pRB might be involved in the 
molecular etiology of ameloblastomas. 
6. The expression of pRB might be influenced by tumor size and age of 
the patients in ameloblastomas. Moreover, tumor size might also 
influence the expression of HBp17/FGFBP-1. 
7. The process of tumor growth and invasion in SMA might be same as 
that in UA. 
Conclusion: The HBp17/FGFBP-1, FGF-1, FGF-2, CD34, p53, pRB and Ki67 play 
important roles in the development and progression of ameloblastomas. 
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Figure Legends 
Figure Legends 
Figure 1: Hematoxylin and Eosin staining. Follicular pattern (1A), Plexiform 
pattern (1B) (x200).  
Figure 2: Immunohistochemical staining for HBp17/FGFBP-1. 
Immunohistochemical reactivity for HBp17/FGFBP-1 was mainly observed in 
the membrane and cytoplasm of the peripheral/basal cells, in the squamous 
cells as well as in the stellate reticulum-like cells. The strongest staining 
intensity was seen in the squamous cells and in the peripheral/basal cells. 2A: 
Follicular pattern, 2B: Plexiform pattern. (x200); 2C: Follicular pattern, 2D: 
Plexiform pattern. (x400). 
Figure 3: Immunohistochemical staining for FGF-1.  
Immunohistochemical reactivity for FGF-1 was mainly observed in the 
squamous cells and in the cytoplasm of the peripheral/basal cells with some 
FGF-1-positive cells expanding into the stellate reticulum-like cell areas. 
Squamous cells and peripheral/basal cells exhibited strong staining intensity. 
3A: Follicular pattern, 3B: Plexiform pattern. (x200); 3C: Follicular pattern, 3D: 
Plexiform pattern. (x400). 
Figure 4: Immunohistochemical staining for FGF-2.  
The expression of FGF-2 in ameloblastoma was mainly detected in the 
membrane and in the cytoplasm of the peripheral/basal cells as well as in the 
squamous cells with some FGF-2-positive cells spreading to the stellate 
reticulum-like cells. The stellate reticulum like cells areas were found weaker 
staining intensity compare to those in squamous cells and in the 
peripheral/basal cells areas. 4A: Follicular pattern, 4B: Plexiform pattern. 
(x200); 4C: Follicular pattern, 4D: Plexiform pattern. (x400). 
Figure 5: Immunohistochemical staining for CD34.  
Tumor microvessels with strong staining intensity of CD34 in the endothelial 
cells showed slightly irregular shaped, tortuous and dilated form in the stroma 
(Figure 5A, 5B, 5C, 5D). Follicular patterns (Figure 5A, 5C) showed many small 
microvessels with slightly irregular shape, whereas microvessels in plexiform 
patterns were scattered with dilated shape (Figure 5B, 5D). 5A: Follicular 
pattern, 5B: Plexiform pattern. (x200); 5C: Follicular pattern, 5D: Plexiform 
pattern. (x400). 
Figure 6: Immunohistochemical staining for p53.  
The immunohistochemical reactivity for p53 was detected in the nuclei of 
peripheral/basal cells with some p53-positive cells spreading to the stellate 
reticulum-like cells. The p53-positive cells in the reticulum-like cell area showed 
lower intensity than that in the peripheral/basal cell area. 6A: Follicular pattern, 
6B: Plexiform pattern. (x200); 6C: Follicular pattern, 6D: Plexiform pattern. 
(x400). 
Figure 7: Immunohistochemical staining for pRB.  
Immunohistochemical reactivity for pRB in ameloblastomas was mainly 
observed in the nuclei of the tumor cells. The pRB-positive cells in the 
peripheral/basal areas exhibited stronger staining intensity than those in the 
stellate reticulum-like areas. 7A: Follicular pattern, 7B: Plexiform pattern. 
(x200); 7C: Follicular pattern, 7D: Plexiform pattern. (x400). 
Figure 8: Immunohistochemical staining for Ki67.  
The expression of Ki67 protein in ameloblastomas was observed in nuclei of 
tumor cells with strong immunostaining intensity. A few scattered Ki67-positive 
cells were observed in the peripheral/basal cells and occasionally seen in the 
stellate reticulum-like cells. There is no significant difference in an intensity of 
Ki67-positive cells between in the stellate reticulum-like cell area and in the 
peripheral/basal cell area. 8A: Follicular pattern, 8B: Plexiform pattern. (x200); 
8C: Follicular pattern, 8D: Plexiform pattern. (x400). 
Figure 9: Double Ki67-CD34 antigens staining.  
Follicular patterns where tumor islands with high expression of Ki67 showed 
many small microvessels with irregular shape (Figure 9A, 9B) whereas plexiform 
patterns where tumor islands with high expression of Ki67 showed few 
microvessels with dilated shape (Figure 9C, 9D). 9A: Follicular pattern, 9B: 
Plexiform pattern. (x200); 9C: Follicular pattern, 9D: Plexiform pattern. (x400). 
Figure 10: Scatter plots showing the correlation between Ki67 and p53  
10A: No correlation between the Ki67 LI and p53 LI. 
10B: Correlation between the Ki67 dEI and p53 dEI. Correlation lines with 
asterisk * showing the significant correlation between p53 and Ki67 (blue line). 
 Figure 11:  Scatter plots showing the correlation between pRB and Ki67, p53. 
11A: Correlation between the pRB LI and Ki67 LI, p53 LI. Correlation lines with 
asterisk * showing the significant correlation between pRB LI and Ki67 LI (red 
line), p53 LI (blue line). 11B: Correlation between the pRB dEI and Ki67 dEI, p53 
dEI. Correlation lines with asterisk * showing the significant correlation 
between pRB dEI and Ki67 dEI (red line), p53 dEI (blue line).  
Figure 12:  Scatter plots showing the correlation between Ki67 and microvessel. 
12A: No correlation between the expression of Ki67 and MVD. 12B: Correlation 
between the expression of Ki67 and pTS. Correlation lines with asterisk * 
showing the significant correlation between pTS and Ki67 LI (blue line), Ki67 dEI 
(red line). 
Figure 13:  Scatter plots showing the correlation between HBp17/FGFBP-1 and 
FGF-1, FGF-2, microvessels.  
13A: Correlation between the HBp17/FGFBP-1 dEI and FGF-1 dEI, FGF-2 dEI. 
Correlation lines with asterisk * showing the significant correlation between 
HBp17/FGFBP-1 dEI and FGF-1 dEI (red line), FGF-2 dEI (blue line). 13B: 
Correlation between the HBp17/FGFBP-1 dEI and MVD, pTS. Correlation lines 
with asterisk * showing the significant correlation between HBp17/FGFBP-1 dEI 
and MVD (red line), pTS (blue line) 
Figure 14: Scatter plots showing the correlation between Ki67 with 
HBp17/FGFBP-1, FGF-1, FGF-2.  
The correlation lines with asterisk * showing the significant correlation 
between Ki67 dEI and HBp17/FGFBP-1 dEI (green line), FGF-1 dEI (blue line), 
FGF-2 dEI (red line).  
Figure 15:  Scatter plots showing the correlation between p53 and 
HBp17/FGFBP-1, FGF-1, FGF-2, microvessels.  
15A: Correlation between p53 and HBp17/FGFBP-1, FGF-1, FGF-2. Correlation 
lines with asterisk * showing the significant correlation between p53 dEI and 
HBp17/FGFBP-1 dEI (green line), FGF-1 dEI (red line), FGF-2 dEI (blue line). 15B: 
Correlation between p53 and MVD, pTS. Correlation lines with asterisk * 
showing the significant correlation between p53 dEI and MVD (red line), pTS 
(blue line).   
Figure 16: Scatter plots showing the correlation between the estimated tumor 
volume and the expression of HBp17/FGFBP-1, pRB.  
The correlation lines with asterisk * showing the significant correlation 
between the estimated tumor volume and HBp17/FGFBP-1 dEI (blue line), pRB 
dEI (red line). 
 
  
 
 
Tables 
Table 1: Primary antibody and Secondary antibody 
 
 
Primary antibody Secondary antibody 
Monoclonal Mouse IgG1 anti 
HBp17/FGFBP-1 antibody (MAB1593, 
R&D systems, Minneapolis, USA,  diluted 
1:100) 
Goat anti Mouse IgG (H+L) – HRP 
(Bio-Rad Laboratories, CA, USA, 
diluted 1:100) 
Polyclonal Rabbit anti FGF1 antibody 
(Santa Cruz, CA, diluted 1:100) 
Labeled polymer-HRP anti-Rabbit 
(Dako, Glostrup, Denmark, Ready-
to-Use) 
Monoclonal Mouse anti FGF2 antibody 
(abcam, Tokyo, Japan, diluted 1:2000) 
Labeled polymer-HRP anti-Mouse 
(Dako, Ready-to-Use) 
Monoclonal Mouse anti CD34 class II 
antibody (clone QBEnd10, N1632, Dako, 
Ready-to-Use) 
Labeled polymer-HRP anti-Mouse 
(Dako, Ready-to-Use) 
Monoclonal Mouse anti p53 antibody 
(clone DO-7, M7001, Dako, diluted 1:50) 
Labeled polymer-HRP anti-Mouse 
(Dako, Ready-to-Use) 
Monoclonal Mouse anti pRB antibody 
(Rb (IF8): sc-102, Santa Cruz, diluted 
1:100) 
Labeled polymer-HRP anti-Mouse 
(Dako, Ready-to-Use) 
Monoclonal Mouse anti Ki67 antibody 
(clone MIB-1, M7240, Dako, diluted 
1:100) 
Labeled polymer-HRP anti-Mouse 
(Dako, Ready-to-Use) 
 
 
  
Table 2: Samples of study 
 
Gender SMA UA DA EA 
Malignant 
ameloblastoma 
Ameloblastic 
carcinoma 
15 Men 11 3 0 0 0 1 
16 Women 12 3 0 0 0 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3 A, B: Correlation between p53, pRB and Ki67. Spearman’s rank 
correlation test, asterisk * indicates the significant correlation (2-tailed) 
(p<0.05).  
Table 3A: Correlation between p53 LI, pRB LI and Ki67 LI.  The asterisk * 
indicates the significant correlation (2-tailed) (p<0.05). 
 
Spearman’s rho pRB LI P53 LI Ki67 LI 
pRB LI Correlation Coefficient 1 0.867* 0.537* 
 Sig. (2-tailed)  <0.001 0.003 
 N 29 29 29 
P53 LI Correlation Coefficient 0.867* 1 0.317 
 Sig. (2-tailed) <0.001  0.094 
 N 29 29 29 
Ki67 LI Correlation Coefficient 0.537* 0.317 1 
 Sig. (2-tailed) 0.003 0.094  
 N 29 29 29 
 
 
 
 
 
 
 
  
Table 3B: Correlation between p53 dEI, pRB dEI and Ki67 dEI. The asterisk * 
indicates the significant correlation (2-tailed) (p<0.05). 
 
Spearman’s rho pRB dEI P53 dEI Ki67 dEI 
pRB dEI Correlation Coefficient 1 0.903* 0.475* 
 Sig. (2-tailed)  <0.001 0.009 
 N 29 29 29 
P53 dEI Correlation Coefficient 0.903* 1 0.431* 
 Sig. (2-tailed) <0.001  0.02 
 N 29 29 29 
Ki67 dEI Correlation Coefficient 0.475* 0.431* 1 
 Sig. (2-tailed) 0.009 0.02  
 N 29 29 29 
 
 
 
 
 
 
 
 
 
 
  
Table 4: Correlation between Ki67 and MVD, pTS. The asterisk * indicates the 
significant correlation (2-tailed) (p<0.05). 
 
Spearman’s rho MVD pTS 
Ki67 LI Correlation Coefficient 0.27 0.588* 
 Sig. (2-tailed) 0.157 0.001 
 N 29 29 
Ki67 dEI Correlation Coefficient 0.234 0.545* 
 Sig. (2-tailed) 0.221 0.002 
 N 29 29 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5: Correlation between HBp17/FGFBP-1 dEI, FGF-1 dEI, FGF-2 dEI and 
MVD, pTS. Spearman’s rank correlation test, asterisk * indicates the 
significant correlation at the 0.001 level (2-tailed) (p<0.05). 
 
Spearman’s rho HBp17/ 
FGFBP-1 dEI 
FGF-1 
dEI 
FGF-2 
dEI HBp17/ 
FGFBP-1 
dEI 
Correlation Coefficient 1 0.737* 0.803* 
Sig. (2-tailed)  <0.001 <0.001 
N 29 29 29 
FGF-1 dEI Correlation Coefficient 0.737* 1 0.606* 
 Sig. (2-tailed) <0.001  <0.001 
 N 29 29 29 
FGF-2 dEI Correlation Coefficient 0.803* 0.606* 1 
 Sig. (2-tailed) <0.001 <0.001  
 N 29 29 29 
MVD Correlation Coefficient 0.662* 0.759* 0.713* 
 Sig. (2-tailed) <0.001 <0.001 <0.001 
 N 29 29 29 
pTS Correlation Coefficient 0.784* 0.716* 0.913* 
 Sig. (2-tailed) <0.001 <0.001 <0.001 
 N 29 29 29 
Ki67 dEI Correlation Coefficient 0.559* 0.514* 0.387* 
 Sig. (2-tailed) 0.002 0.004 0.038 
 N 29 29 29 
  
Table 6: The correlation with age. Kruskal-Wallis test. The asterisk * indicates 
the significant correlation (2-tailed) (p<0.05). 
 
 Age N Mean Rank Asym. Sig (2-tailed) 
HBp17/FGFBP-1 LI <20 5 9.80 0.340 
20-40 17 15.00  
>40 7 18.71  
FGF-1 LI <20 5 13.00 0.564 
 20-40 17 14.41  
 >40 7 17.86  
FGF-2 LI <20 5 11.00 0.445 
 20-40 17 15.24  
 >40 7 17.29  
p53 LI <20 5 10.06 0.122 
 20-40 17 14.12  
 >40 7 20.29  
pRB LI <20 5 7.60 0.031* 
 20-40 17 14.82  
 >40 7 20.71  
Ki67 LI <20 5 11.40 0.240 
 20-40 17 17.24  
 >40 7 12.14  
(to be continued) 
 
  
 Age N Mean Rank Asym. Sig (2-tailed) 
HBp17/FGFBP-1 dEI <20 5 9.00 0.181 
20-40 17 15.53  
>40 7 18  
FGF-1 dEI <20 5 12.00 0.489 
 20-40 17 14.71  
 >40 7 17.86  
FGF-2 dEI <20 5 13.00 0.537 
 20-40 17 14.35  
 >40 7 18.00  
MVD <20 5 11.60 0.587 
 20-40 17 15.35  
 >40 7 16.57  
pTS <20 5 12.60 0.694 
 20-40 17 14.94  
 >40 7 16.86  
p53 dEI <20 5 9.80 0.192 
 20-40 17 14.96  
 >40 7 18.86  
pRB dEI <20 5 8.60 0.049* 
 20-40 17 14.53  
 >40 7 20.71  
Ki67 dEI <20 5 12.00 0.261 
 20-40 17 17.18  
 >40 7 11.86  
 
Table 7: The correlation of these factors between SMA and UA. Mann-
Whitney U test. The asterisk * indicates the significant correlation (2-tailed) 
(p<0.05). 
 
 Subtype N Mean Rank Asym. Sig (2-tailed) 
HBp17/FGFBP-1 LI UA 6 12.67 0.451 
SMA 23 15.61  
FGF-1 LI UA 6 12.83 0.484 
 SMA 23 15.57  
FGF-2 LI UA 6 12.00 0.333 
 SMA 23 15.78  
p53 LI UA 6 8.50 0.036* 
 SMA 23 16.70  
pRB LI UA 6 10.17 0.118 
 SMA 23 16.26  
Ki67 LI UA 6 15.17 0.957 
 SMA 23 14.96  
(to be continued) 
 
  
 Subtype N Mean Rank Asym. Sig (2-tailed) 
HBp17/FGFBP-1 dEI UA 6 13.50 0.628 
SMA 23 15.39  
FGF-1 dEI UA 6 14.00 0.747 
 SMA 23 15.26  
FGF-2 dEI UA 6 11.33 0.236 
 SMA 23 15.96  
MVD UA 6 13.17 0.554 
 SMA 23 15.48  
pTS UA 6 12.50 0.419 
 SMA 23 15.65  
p53 dEI UA 6 10.83 0.178 
 SMA 23 16.09  
pRB dEI UA 6 10.33 0.132 
 SMA 23 16.22  
Ki67 dEI UA 6 15.17 0.957 
 SMA 23 14.96  
  
Table 8: The expression of HBp17/FGFBP-1, FGF-1, FGF-2, MVD, pTS, p53, 
pRB, Ki67 in benign ameloblastoma (mean± SD) and in ameloblastic 
carcinoma 
 
Factors 
Benign ameloblastomas 
(Mean± SD) 
Ameloblastic Carcinoma 
HBp17/FGFBP-1 LI 34.99±19.57 53.75 
HBp17/FGFBP-1 dEI 21.98±14.96 44.71 
FGF-1 LI 31.45±10.99 52.05 
FGF-1 dEI 30.40±16.57 38.68 
FGF-2 LI 70.38±22.93 83.73 
FGF-2 dEI 54.77±25.16 59.11 
MVD 64.25±23.70 77.80 
pTS 36.87±18.79 37.63 
p53 LI 29.16±12.80 51.56 
p53 dEI 36.87±17.47 71.91 
pRB LI 32.06±20.30 77.37 
pRB dEI 44.52±37.08 138.56 
Ki67 LI 4.32±4.05 2.51 
Ki67 dEI 8.16±7.94 4.42 
 
 
  
 
 
Figures 
Figure 1: Hematoxylin and Eosin staining.  
1A: Follicular pattern, 1B: Plexiform pattern. (x200). 
  
 
 
 
 
 
 
 
 
Figure 2: Immunohistochemical reactivity for HBp17/FGFBP-1.  
2A: Follicular pattern, 2B: Plexiform pattern (x200)  
2C: Follicular pattern, 2D: Plexiform pattern (x400). 
 
 
 
 
 
 
 
   
A B 
A 
C 
B 
D 
  
 
 
 
Figure 3: Immunohistochemical reactivity for FGF-1.  
3A: Follicular pattern, 3B: Plexiform pattern (x200). 
3C: Follicular pattern, 3D: Plexiform pattern (x400). 
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Figure 4: Immunohistochemical reactivity for FGF-2. 
4A: Follicular pattern, 4B: Plexiform pattern. (x200) 
4C: Follicular pattern, 4D: Plexiform pattern. (x400) 
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Figure 5: Immunohistochemical staining for CD34. 
5A: Follicular pattern, 5B: Plexiform pattern. (x200) 
5C: Follicular pattern, 5D: Plexiform pattern. (x400) 
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Figure 6: Immunohistochemical staining for p53.  
6A: Follicular pattern, 6B: Plexiform pattern (x200). 
6C: Follicular pattern, 6D: Plexiform pattern (x400). 
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Figure 7: Immunohistochemical staining for pRB.  
7A: Follicular pattern, 7B: Plexiform pattern. (x200). 
7C: Follicular pattern, 7D: Plexiform pattern. (x400). 
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Figure 8: Immunohistochemical staining for Ki67.  
8A: Follicular pattern, 8B: Plexiform pattern. (x200). 
8C: Follicular pattern, 8D: Plexiform pattern. (x400). 
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Figure 9: Double Ki67-CD34 antigens staining.  
9A: Follicular pattern, 9B: Plexiform pattern. (x200). 
9C: Follicular pattern, 9D: Plexiform pattern. (x400). 
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Figure 10:  Scatter plots showing the correlation between Ki67 and p53  
10 A: No correlation between the Ki67 LI and p53 LI. 
10 B: Correlation between the Ki67 dEI and p53 dEI. The correlation lines with 
asterisk * showing the significant correlation between p53 and Ki67 (blue line). 
 
 
 
 
 
 
 
 
 
Figure 11:  Scatter plots showing the correlation between pRB and Ki67, p53. 
11 A: Correlation between the pRB LI and Ki67 LI, p53 LI. The correlation lines 
with asterisk * showing the significant correlation between pRB LI and Ki67 LI 
(red line), p53 LI (blue line). 11 B: Correlation between the pRB dEI and Ki67 
dEI, p53 dEI. The correlation lines with asterisk * showing the significant 
correlation between pRB dEI and Ki67 dEI (red line), p53 dEI (blue line).  
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Figure 12:  Scatter plots showing the correlation between Ki67 and microvessel. 
12 A: No correlation between the expression of Ki67 and MVD. 12 B: 
Correlation between the expression of Ki67 and pTS. The correlation lines with 
asterisk * showing the significant correlation between pTS and Ki67 LI (blue 
line), Ki67 dEI (red line).  
 
 
 
 
 
 
 
 
 
Figure 13:  Scatter plots showing the correlation between HBp17/FGFBP-1 and 
FGF-1, FGF-2, microvessels. 13 A: Correlation between the HBp17/FGFBP-1 dEI 
and FGF-1 dEI, FGF-2 dEI. The correlation lines with asterisk * showing the 
significant correlation between HBp17/FGFBP-1 dEI and FGF-1 dEI (red line), 
FGF-2 dEI (blue line). 13 B: Correlation between the HBp17/FGFBP-1 dEI and 
MVD, pTS. The correlation lines with asterisk * showing the significant 
correlation between HBp17/FGFBP-1 dEI and MVD (red line), pTS (blue line) 
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Figure 14: Scatter plots showing the correlation between Ki67 with 
HBp17/FGFBP-1, FGF-1, FGF-2. The correlation lines with asterisk * showing the 
significant correlation between Ki67 dEI and HBp17/FGFBP-1 dEI (green line), 
FGF-1 dEI (blue line), FGF-2 dEI (red line).  
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Figure 15:  Scatter plots showing the correlation between p53 and 
HBp17/FGFBP-1, FGF-1, FGF-2, microvessels. 15 A: Correlation between p53 
and HBp17/FGFBP-1, FGF-1, FGF-2. The correlation lines with asterisk * 
showing the significant correlation between p53 dEI and HBp17/FGFBP-1 dEI 
(green line), FGF-1 dEI (red line), FGF-2 dEI (blue line). 15 B: Correlation 
between p53 and MVD, pTS. The correlation lines with asterisk * showing the 
significant correlation between p53 dEI and MVD (red line), pTS (blue line).   
 
 
 
 
 
 
 
 
 
Figure 16: Scatter plots showing the correlation between the estimated tumor 
volume and the expression of HBp17/FGFBP-1, pRB. The correlation lines with 
asterisk * showing the significant correlation between the estimated tumor 
volume and HBp17/FGFBP-1 dEI (blue line), pRB dEI (red line).  
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